CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...